Lindsey Anderson, MA, CCC-SLP | |
605 Spruce St, Aurora, SD 57002-2123 | |
(605) 690-8991 | |
Not Available |
Full Name | Lindsey Anderson |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 605 Spruce St, Aurora, South Dakota |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1649949926 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 858-SLP (South Dakota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Lindsey Anderson, MA, CCC-SLP 605 Spruce St, Aurora, SD 57002-2123 Ph: () - | Lindsey Anderson, MA, CCC-SLP 605 Spruce St, Aurora, SD 57002-2123 Ph: (605) 690-8991 |
News Archive
Children born to women who were exposed to higher arsenic during pregnancy have a greater risk of infections and respiratory symptoms within their first year of life, a Dartmouth College-led study shows.
In a study published this month in the Journal of Alzheimer's Disease, researchers from the University of Aberdeen report that the drug memantine, used for the treatment of Alzheimer's disease and praised as "the first and only representative of a new class of Alzheimer drugs" works in fact similar to other existing compounds, and is beneficial only in a narrow concentration range.
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. today announced that treatment with its lead compound, Homspera, in combination with a DNA vaccine utilizing Scancell's ImmunoBody technology significantly improved the immune response of the vaccine in an animal model.
A growing body of basic animal research and studies of abused and neglected children provide a strong basis of support for the hypothesis that individuals with particular genotypes are at greater risk for depression, anxiety disorders, and problems with the abuse of alcohol and other substances.
Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.
› Verified 8 days ago